Moderna, Inc. 8-K Report: Key Insights on August 1, 2025 Filing

Based on the provided XML section of a financial report, here are the extracted key information and insights:

1. Entity Information:

• Name: Moderna, Inc.
• CIK Number: 0001682852
• Stock Ticker: MRNA
• Exchange: NASDAQ
• Company Address: 325 Binney Street, Cambridge, MA 02142
• Phone Number: 617-714-6500

2. Filing Details:

• Filing Type: 8-K (Current Report)
• Filing Date: August 1, 2025

3. Common Stock Information:

• Par Value: $0.0001 per share

4. Period of Reporting:

• Report Date: August 1, 2025 (the start and end date of the reporting period are the same, indicating a specific event or disclosure on that date).

5. Additional Notes:

• The report appears to be an 8-K, which is typically used to report major events that shareholders should know about. However, the specific details of the events or changes being reported are not provided in this excerpt.

Insights:

• As an 8-K filing, this indicates that Moderna may have experienced a significant event that necessitated immediate disclosure, which could be related to financial performance, a new product announcement, changes in leadership, or other material events.
• The specific date of August 1, 2025, suggests that stakeholders should be vigilant for updates or further disclosures regarding the company's operations or financial standing around this date.
• The par value of $0.0001 indicates that the common stock is likely intended for a high volume of shares, which is common in biotech and tech companies aiming for growth and investment.

Overall, while the provided section contains basic identifying information, further context from the full 8-K would be necessary to fully understand the implications of this filing.